# Clinical Trials Data KIT - Document 27

# Colorectal Cancer Awareness, Research, Education and Screening (CARES)

## Clinical Trial: https://clinicaltrials.gov/study/NCT01804179

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Racially-ethnically diverse adult men and women\n\* Average risk individuals who have no personal diagnosis, or presumptive symptoms of colorectal cancer (CRC), or are not at high risk\n\* Self-report as not current on screening\n\* Provide at least two forms of contact information and contact information of a relative (not living with respondent) to facilitate follow-up contacts\n\* Are able to speak, read and write English because the instruments and CARES intervention are available only in English at this time. We recognize that interventions are needed for non-English speaking populations, therefore, once we find promise in the English language CARES intervention materials, we will move forward with conducting other studies that involve translation of measures and cultural adaptation of the CARES intervention materials into Spanish or Haitian Creole.\n\nExclusion Criteria:\n\n\* Individuals who have participated in a CRCS research study in the past 1 year will not be eligible for this study.\n\* Recent screening criteria relates to not having had I-FOBT within the previous year, flex sig within the previous 5 years, a double-contrast barium enema (DCBE) x-ray with the previous 5 years, or a colonoscopy within the previous 10 years.\n\* Within the recruitment and intervention frame, high risk individuals (due to strong family history, ulcerative colitis, polyposis syndromes) are excluded because they may be eligible for CRC screening before age 50, and the preferred screening option is certainly colonoscopy which is beyond the primary focus of the current study.",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "50 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, the eligibility criteria focus on individuals who are at average risk for colorectal cancer (CRC) and do not highlight gene mutations as a consideration for inclusion or exclusion. The core criteria are whether participants are current on screening, have a high risk due to family history, or specific conditions like ulcerative colitis or polyposis syndromes.  
  
Since a KIT gene mutation is not mentioned as an exclusion criterion, it's unlikely that such a mutation directly impacts eligibility for this trial. The primary concern seems to be keeping the participant selection aligned with average-risk individuals as well as recent CRC screening history.  
  
If a patient with a KIT gene mutation does not fall under the other exclusion criteria (e.g., high-risk based on family history or specific conditions), it appears they could still be eligible for the trial. However, it's always advisable to verify this with the trial coordinators to ensure there are no additional considerations specific to gene mutations.